IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 2 1 2002

Group Art: 1

Jules B. Puschet

In re Applica

: METHOD OF DETERMINING VOLUME : DEPENDENT HYPERTENSION THROUGH

TECH CENTER 1600/2900

: PROTEIN REDUCTION IN PHOSPHORYLATION

: OR CONCENTRATION AND RELATED APPARATUS

Serial No.: 09/990,432

: Attorney Docket No.: 205204-00009

Filed: November 21, 2001

INFORMATION DISCLOSURE STATEMENT

Eckert Seamans Cherin & Mellott 600 Grant Street, 44th Floor Pittsburgh, PA 15219 June 11, 2002

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to the provisions of 37 CFR Sections 1.56, 1.97 and 1.98, Applicant submits herewith copies of the prior art documents cited on the attached Forms PTO/SB/08A and PTO/SB/08B for consideration during prosecution of the subject Application.

The cited art, preceded by an asterisk, is discussed at page 1, line 13 through page 3, line 14, and page 6, line 6 through page 9, line 23, and also page 13, line 22 through page 14, line

This Statement is filed solely for the purpose of complying with the pertinent rules of the Office and is not intended to be a substitute for an independent evaluation by the Examiner of the art cited or an independent search by the Examiner, and no representation of any nature is made or intended by the filing of this Statement.

In addition to the art cited on Forms PTO/SB/08A and PTO/SB/08B, applicants and/or their attorneys may have been exposed to or considered additional art relating to the general class of the subject matter of the invention. However, if in fact such exposure or consideration has occurred to the best of their recall or judgment, none of such art is prior art which is more relevant than the art cited.

Respectfully submitted,

Arnold B. Silverman Registration No. 22,614 Attorney for Applicant

(412) 566-2077

Please	type a	plus	sign	(+)	inside	this	box	\rightarrow
	-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	P	9				~~~	

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

PRADEMA

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known					
Application Number	09/990,432				
Filing Date	November 21, 2001				
First Named Inventor	Jules B. Puschett				
Group Art Unit	1641				
Examiner Name	DECE				
Attorney Docket Number	205204-00009				

						HIN O 1	2002	
	U.S. PATENT DOCUMENTS JUN 2 1							
Examiner Initials*	Cite No.1	l Number	cument (ind Code ² if known)	Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, What February ENTER Passages of Hele MENTER Figures Appear	600/29	
		5,049,358		Lau	09/17/1991			
		5,478,748		Akins, Jr. et al.	12/26/1995			
		5,496,703		Babish et al.	03/05/1996			
		5,686,310		Haystead et al.	11/11/1997			
		5,856,082		Aebersold et al.	01/05/1999			
		-						
ļ								
			+			<u> </u>		
			_		- 			
					 -			
					1			

	FOREIGN PATENT DOCUMENTS										
Examiner	Cite	Foreign Patent Docume			Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant				
Initials*	No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶			
			WO 96/21861 /		Alam	07/18/1996					
								igspace			
		 						+			
							 	+			
					,			+-1			
						<u> </u>		+			

Examiner Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	1							
	1011	7	HOOD et al., Immunology, Second Edition, (1984), pp. 52-58					
*	JUN 17	2002	WEINMAN et al., Protein Kinase C. Activates the Renal Apical Membrane No. Exchanger, J. Membrane Biol., (1986), pp. 133-139, Vol. 93	'a+/H+				
*	PATE TRAD	MARKO	WEINMAN et al., cAMP-associated inhibition of Na ⁺ -H ⁺ exchanger in rabb brush-border membranes, Am. J. Physiol., (1987), pp. F19-F25, Vol. 252	it kidney				
*			CHEN et al., Volume Expansion-Induced Changes in Renal Tubular Membras Phosphorylation, Biochemical and Biophysical Research Communications, (F. 1987), pp. 74-80, Vol. 143, No. 1		_			
*			LAMINSKI, et al., <i>Phosphorylation of Endogenous Protein in Primate Kidne Cyclic AMP</i> , Comp. Biochem. Physiol., (1992), pp. 267-273, Vol. 103B, No. Britain					
*			SCHENK et al., <i>The Pathogenesis of DOCA-Salt Hypertension</i> , J. Pharmacol. Methods, (1992), pp. 161-170, Vol. 27, No. 3	Toxicol				
			NISHI et al, Renal Na ⁺ , K ⁺ -ATPase in Dahl salt-sensitive rats: K ⁺ dependence, effect of cell environment and protein kinases, Acta Physiol Scand., (1993), pp. 377-384, Vol. 149					
			GAIA et al., Heat shock protein 72 in cardiac and skeletal muscles during hype Molecular and Cellular Biochemistry, (1995), pp. 1-7, Vol. 146, The Netherland			,		
*			CUSTER, et al., Identification of a new gene product (diphor-1) regulated by phosphate, Am. J. Physiol., (1997), pp. F801-F806, Vol. 273 (Renal Physiol.					
*			WHITE, et al., A PDZ domain-containing protein with homology to Diphor-1 human chromosome 1q21, Ann. Hum. Genet., (1998), pp. 287-290, Vol. 62, C					
*			IKEMOTO, et al. <i>Identification of a PDZ-domain-containing protein that inte scavenger receptor class B type 1</i> , Proceedings of the National Academy of S 6, 2000), pp. 6538-6543, Vol. 97, No. 12					
			<u> </u>					
	Examiner Signature			Date Considered				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.



TECH CENTER 1600/2900

Please type a plus sign (+) inside this box -> +

PTO/SB/21 (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE work Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 09/990.432 Application Number JUN 1 7 2002 TRANSMITTAL November 21, 2001 **Filing Date FORM** Jules B. Puschett **First Named Inventor** 1641 Group Art Unit be used for all correspondence after initial filing) **Examiner Name** 205204-00009 Attorney Docket Number Total Number of Pages in This Submission **ENCLOSURES** (check all that apply) After Allowance Communication Assignment Papers Fee Transmittal Form (for an Application) to Group Appeal Communication to Board Fee Attached Drawing(s) of Appeals and Interferences Licensing-related Papers Appeal Communication to Group Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition After Final **Proprietary Information** Petition to Convert to a Affidavits/declaration(s) **Provisional Application** Status Letter Power of Attorney, Revocation Change of Correspondence Address Other Enclosure(s) (please Extension of Time Request identify below): Terminal Disclaimer RETURN POSTCARD Express Abandonment Request Request for Refund PTO/SB/08A PTO/SB/08B Information Disclosure Statement CD, Number of CD(s). 28 REFERENCES Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Arnold B. Silverman Individual name Signature June 11, 2002 Date **CERTIFICATE OF MAILING** I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class

mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: June 11, 2002 Arnold B. Silverman Typed or printed name June 11, 2002 Signature Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for f	form 1449B	/PTO		Complete if Known				
	Ι	NFO	RMATION	DISCLOSURE	Application Number 09/990,432				
	S	TAT	EMENT BY	Y APPLICAND PE	Filing Date	November 21	, 2001		
				Y APPLICAND	First Named Inventor	Jules B. Puscl	nett		
			(use as mai	any sheets as necessary)	Group Art Unit	1641			
				TRADEMINE	Examiner Name				
	Sheet		l of	2 .	Attorney Docket Number	205204-00009			
	Examiner Initials	Cite No. ¹		author (in CAPITAL LETTERS), title of the article (when app atalog, etc.), date, page(s), volume-issue number(s), publisher,		ine, journal,	T²		
*				Cleavage of Structural Proteins during te T4, Nature (August 15, 1970), pp. 680		of			
*				al., Adenohypophyseal Secretory Granul Vol. 246, No. 23, Issue Dec. 10, U.S.A.), pp.			
*				al., Protein Kinase Activity in Membra 173), pp. 483-492, Vol. 132, Great Brita		Brain, J.			
*			UEDA et al., Regulation of Endogenous Phosphorylation of Specific Proteins in Synaptic Membrane Fractions from Rat Brain by Adenosine 3':5'-Monophosphate*, J. Biol. Chem., (1973), pp. 8295-8305, Vol. 248, No. 23, Issue Dec. 10, U.S.A.						
*			CHANG, et al., Cyclic Adenosine Monophosphate-dependent Phosphorylation of Specific Fat Cell Membrane Proteins by an Endogenous Membrane-bound Protein Kinase, J. Biol Chem, (1974), pp. 6854-6865, Vol. 249, No. 21, Issue Nov. 10, U.S.A.						
*			PINKETT, et al., Phosphorylation of Muscle Plasma Membrane Protein by a Membrane-Bound Protein Kinase, Biochimica et Biophysica Acta, (1974), pp. 379-387, Vol. 372, The Netherlands						
*			BRADFORD, A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding, Anal. Biochem, (1976), pp. 248-254, Vol. 72						
*	,		PAMNANI et al., Altered activity of the sodium-potassium pump in arteries of rats with steroid hypertension, Clinical Science and Molecular Medicine, (1978), pp. 41s-43s, Vol. 55						
*			HUANG, et al. Bilateral Renal Function Responses to Converting Enzyme Inhibitor (SQ 20, 881) in Two-Kidney, One Clip Goldblatt Hypertensive Rats, Hypertension, (May-June 1981), pp. 285-293, Vol. 3, No. 3						
*			HAMMERMAN, et al., Cyclic AMP-dependent Protein Phosphorylation in Canine Renal Brush-Border Membrane Vesicles Is Associated with Decreased Phosphate Transport*, J. Biol. Chem., (1982), pp. 992-999, Vol. 257, No.2, Issue January 25, U.S.A.						
*			KEMPSON et al., Inhibition of Renal Brush Border Phosphate Transport and Stimulation of Renal Gluconeogenesis by Cyclic AMP and Parathyroid Hormone, Biochem., Pharmacol., (1983), pp. 1533-1537, Vol. 32, No. 9, Great Britain						

.